Articles from Prodeon Medical

The Urocross® Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.

SUNNYVALE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Prodeon Medical, Inc., a medical device company developing a minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), today announced the successful completion of patient enrollment in its Expander-2 Pivotal Trial. This multi-center, randomized, blinded, controlled study is designed to evaluate the safety and efficacy of the company’s novel Urocross® Expander System and the Urocross® Retrieval Sheath, a minimally invasive, non-permanent implant-based treatment for patients with Lower Urinary Tract Symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).